These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

482 related items for PubMed ID: 25078275

  • 1. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
    Vennegoor A, Rispens T, Van Oosten BW, Wattjes MP, Wondergem MJ, Teunissen CE, Van der Kleij D, Uitdehaag BM, Polman CH, Killestein J.
    Mult Scler; 2015 Apr; 21(4):481-4. PubMed ID: 25078275
    [Abstract] [Full Text] [Related]

  • 2. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M, Plavina T, Khatri BO, Fox RJ, Goelz SE.
    Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
    [Abstract] [Full Text] [Related]

  • 3. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.
    van Kempen ZL, Leurs CE, Vennegoor A, Wattjes MP, Rispens T, Uitdehaag BM, Killestein J.
    Mult Scler; 2017 Jun; 23(7):995-999. PubMed ID: 28112019
    [Abstract] [Full Text] [Related]

  • 4. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Vennegoor A, van Rossum JA, Polman CH, Wattjes MP, Killestein J.
    Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
    [Abstract] [Full Text] [Related]

  • 5. Assessing understanding of individual risk and symptoms of progressive multifocal leukoencephalopathy in patients prescribed natalizumab for multiple sclerosis.
    Rath L, Vijiaratnam N, Skibina O.
    Intern Med J; 2017 Feb; 47(2):194-199. PubMed ID: 27862809
    [Abstract] [Full Text] [Related]

  • 6. Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.
    Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, Perez-Hoyos S, Sanchez A, Vermersch P, Ruet A, de Sèze J, Labauge P, Vukusic S, Papeix C, Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Montalban X, Brassat D, Comabella M, Biomarkers and Response to Natalizumab for Multiple Sclerosis Treatment (BIONAT), Best EScalation Treatment in Multiple Sclerosis (BEST-MS), and the Société Francophone de la Sclérose En Plaques (SFSEP) Network.
    Ann Neurol; 2017 Aug; 82(2):186-195. PubMed ID: 28681388
    [Abstract] [Full Text] [Related]

  • 7. Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment.
    Fabis-Pedrini MJ, Xu W, Burton J, Carroll WM, Kermode AG.
    J Clin Neurosci; 2016 Mar; 25():145-7. PubMed ID: 26541323
    [Abstract] [Full Text] [Related]

  • 8. Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks.
    Maloney E, Molloy A, Al Hussona M, O'Donnell L, Killeen R, McGuigan C.
    J Neurol; 2017 Feb; 264(2):401-403. PubMed ID: 28039520
    [No Abstract] [Full Text] [Related]

  • 9. Early onset of natalizumab-related progressive multifocal leukoencephalopathy.
    Damasceno A, von Glehn F, Martinez AR, Longhini AL, Deus-Silva L, Brandão CO, Santos LM, Damasceno BP.
    Mult Scler; 2011 Nov; 17(11):1397-8. PubMed ID: 21900356
    [No Abstract] [Full Text] [Related]

  • 10. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped.
    Rispens T, Vennegoor A, Wolbink GJ, Polman CH, Killestein J.
    Mult Scler; 2012 Jun; 18(6):899-901. PubMed ID: 22183929
    [Abstract] [Full Text] [Related]

  • 11. Asymptomatic Progressive Multifocal Leukoencephalopathy Associated with Natalizumab: Diagnostic Precision with MR Imaging.
    Hodel J, Outteryck O, Dubron C, Dutouquet B, Benadjaoud MA, Duhin E, Verclytte S, Zins M, Luciani A, Rahmouni A, Pruvo JP, Vermersch P, Leclerc X.
    Radiology; 2016 Mar; 278(3):863-72. PubMed ID: 26436861
    [Abstract] [Full Text] [Related]

  • 12. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases.
    Peaureaux D, Pignolet B, Biotti D, Bucciarelli F, Gaina J, Bucur C, Clanet M, Martin-Blondel G, Brassat D.
    Mult Scler; 2015 Apr; 21(5):671-2. PubMed ID: 25305251
    [No Abstract] [Full Text] [Related]

  • 13. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 Apr; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
    Wattjes MP, Wijburg MT, Vennegoor A, Witte BI, Roosendaal SD, Sanchez E, Liu Y, Martins Jarnalo CO, Richert ND, Uitdehaag BM, Barkhof F, Killestein J.
    Mult Scler; 2016 Aug; 22(9):1174-83. PubMed ID: 26564995
    [Abstract] [Full Text] [Related]

  • 15. Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen.
    Hervás JV, Presas-Rodríguez S, Crespo-Cuevas AM, Canento T, Lozano-Sánchez M, Massuet-Vilamajó A, Ramo-Tello C.
    Neurodegener Dis Manag; 2015 Oct; 5(5):399-402. PubMed ID: 26517599
    [Abstract] [Full Text] [Related]

  • 16. To PLEX or not to PLEX in natalizumab-associated PML.
    Tyler KL, Vollmer TL.
    Neurology; 2017 Mar 21; 88(12):1108-1109. PubMed ID: 28228561
    [No Abstract] [Full Text] [Related]

  • 17. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R, Mostosi C, Quivron B, Delberghe X, El Hafsi K, Lysandropoulos AP.
    Clin Ther; 2016 Mar 21; 38(3):670-5. PubMed ID: 26856928
    [Abstract] [Full Text] [Related]

  • 18. [Progressive multifocal leukoencephalopathy associated to natalizumab: the importance of magnetic resonance imaging in its early diagnosis].
    Martí G, Río J, Rovira À, Auger C, Tintoré M, Sastre-Garriga J, Vidal A, Castilló J, Montalban X.
    Rev Neurol; 2015 Feb 16; 60(4):164-8. PubMed ID: 25670046
    [Abstract] [Full Text] [Related]

  • 19. Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab.
    Toorop AA, van Lierop ZYG, Strijbis EEM, Teunissen CE, Petzold A, Wattjes MP, Barkhof F, de Jong BA, van Kempen ZLE, Killestein J.
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan 16; 8(1):. PubMed ID: 33051344
    [Abstract] [Full Text] [Related]

  • 20. Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis.
    Clerico M, Artusi CA, Di Liberto A, Rolla S, Bardina V, Barbero P, De Mercanti SF, Durelli L.
    Expert Opin Drug Saf; 2017 Aug 16; 16(8):963-972. PubMed ID: 28641055
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.